An observational study in Use of Methylphenidate in Children and Adolescents, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2017-12-13.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
The use of methylphenidate in children and adolescents in France from 2010 to 2015
To describe the use of methylphenidate in children and adolescents in France from 2010 to 2015
Children and adolesents who are users of methylphenidate
Inclusion Criteria:
Children and adolescents who are users of methylphenidate, 2010 to 2015
Other: users of methylphenidate
Children and adolescents who are users of methylphenidate, 2010 to 2015
use of methylphenidate over time
Describe of the use of methylphenidate over time to determine the impact of regulatory information of appropriate prescription conditions of use in September 2012
Time frame: 6 years
Describe methylphenidate patterns of use over time
Pharmaceutical specialties (immediate or extended release forms) prescribed by type of delivery: initial or renewals. Profile of prescribers: hospital or private practice (general practitioners, specialists) depending on type of prescription (initial or renewal); geographical distribution of the prescribers Profile of patients: sex, average age and age classes (0-23 months, 2-5 years, 6-11 years, 12-17 years), socioeconomic status, long-lasting diseases status for psychosis, severe personality disorder, mental retardation. Pattern of methylphenidate use: duration of treatment, prolonged use, interruption of treatment.
Time frame: 6 years
Co-prescription of methylphenidate and non-psychostimulant psychotropic drugs
Time frame: 6 years
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris